MCID: ADN011
MIFTS: 66

Adenoid Cystic Carcinoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Neuronal diseases, Oral diseases, Rare diseases, Skin diseases

Aliases & Classifications for Adenoid Cystic Carcinoma

MalaCards integrated aliases for Adenoid Cystic Carcinoma:

Name: Adenoid Cystic Carcinoma 12 12 76 53 6 15 73
Salivary Gland Adenoid Cystic Carcinoma 12 55 15
Cylindroma 12 53
Adenoid Cystic Carcinoma of Salivary Gland 73
Carcinoma, Adenoid Cystic 44
Eccrine Dermal Cylindroma 73
Carcinoma Adenoid Cystic 55
Adenoid Cystic Cancer 12
Adenocystic Carcinoma 53
Carcinoma, Cribriform 73
Cribriform Carcinoma 53

Classifications:



External Ids:

Disease Ontology 12 DOID:0080202 DOID:4866
MeSH 44 D003528
NCIt 50 C2970
SNOMED-CT 68 11671000

Summaries for Adenoid Cystic Carcinoma

NIH Rare Diseases : 53 Adenoid cystic carcinoma (ACC) is a rare form of adenocarcinoma, a type of cancer that begins in glandular tissues. It most commonly arises in the major and minor salivary glands of the head and neck. It can also occur in the breast, uterus, or other locations in the body. Symptoms depend on the tumor's location. Salivary gland tumors may cause painless masses in the mouth or face. Tumors of the lacrimal gland may cause a bulging eye or changes in vision. Those affecting the windpipe or voice box may cause respiratory symptoms or changes in speech, respectively. Advanced tumors may cause pain and/or nerve paralysis, as ACC often spreads along the nerves. It may also spread through the bloodstream. It spreads to the lymph nodes in about 5% to 10% of cases. The cause of ACC is currently unknown. It typically does not run in families. Treatment depends on many factors and may include surgery, radiation, and/or chemotherapy. Unfortunately, ACC is typically an aggressive form of cancer that has a poor long-term outlook.

MalaCards based summary : Adenoid Cystic Carcinoma, also known as salivary gland adenoid cystic carcinoma, is related to prostate adenoid cystic carcinoma and lung adenoid cystic carcinoma, and has symptoms including pain An important gene associated with Adenoid Cystic Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Fentanyl and Histamine have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, breast and lung, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A salivary gland carcinoma that is characterized by a distinctive pattern in which abnormal nests or cords of epithelial cells surround and/or infiltrate ducts or glandular structures within the affected organ. These structures are typically filled with a mucous-like material or contain abnormal fibrous membranes.

Wikipedia : 76 Adenoid cystic carcinoma (sometimes referred to as adenocyst, malignant cylindroma, adenocystic,... more...

Related Diseases for Adenoid Cystic Carcinoma

Diseases related to Adenoid Cystic Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 368)
# Related Disease Score Top Affiliating Genes
1 prostate adenoid cystic carcinoma 34.5 HRAS PIK3CA
2 lung adenoid cystic carcinoma 34.3 HRAS KIT KRAS NFIB PIK3CA
3 breast adenoid cystic carcinoma 34.2 ERBB2 KIT NFIB
4 prostate cancer 32.1 AKT1 CCND1 CDH1 ERBB2 HRAS KRAS
5 polymorphous low-grade adenocarcinoma 31.4 CCND1 KIT MUC1 MYB NFIB
6 pleomorphic adenoma 31.4 ERBB2 KRT14 MUC1 TP53
7 adenocarcinoma 31.2 TP53 PTEN PIK3CA MUC1 KRAS KIT
8 squamous cell carcinoma 30.9 AKT1 CCND1 CDH1 ERBB2 HRAS MUC1
9 mucoepidermoid carcinoma 30.9 ERBB2 KRT14 KRT7 MUC1
10 small cell carcinoma 30.8 KIT KRT7 PTEN TP53
11 sarcoma 30.6 HRAS KIT KRAS PIK3CA TP53
12 epithelial-myoepithelial carcinoma 30.6 FBXW7 HRAS KRT14 KRT7 TP53
13 basaloid squamous cell carcinoma 30.6 KRT14 KRT7 TP53
14 gliosarcoma 30.5 IDH1 PTEN TP53
15 differentiated thyroid carcinoma 30.5 HRAS KRAS TP53
16 necrotizing sialometaplasia 30.4 KIT KRT7 TP53
17 teratoma 30.4 KIT KRT7 TP53
18 spiradenoma 30.4 CYLD KRT14 KRT7 TP53
19 dermoid cyst 30.4 KIT KRT7 MUC1
20 cavernous hemangioma 30.3 KIT KRT7 MUC1
21 mucinous adenocarcinoma 30.3 KRAS KRT7 MUC1
22 basal cell carcinoma 30.3 CYLD KRT14 KRT7 PTEN TP53
23 nasopharyngeal carcinoma 30.3 AKT1 CCND1 CDH1 HRAS PIK3CA TP53
24 malignant spiradenoma 30.3 KRT7 PIK3CA TP53
25 squamous cell carcinoma, head and neck 30.3 AKT1 CCND1 CDH1 ERBB2 HRAS PIK3CA
26 glioblastoma 30.3 AKT1 CCND1 ERBB2 HRAS IDH1 PIK3CA
27 transitional cell carcinoma 30.2 CDH1 ERBB2 HRAS KRT7 PTEN TP53
28 papilloma 30.2 CCND1 KRT14 KRT7 PTEN TP53
29 renal cell carcinoma, papillary, 1 30.2 ERBB2 HRAS KIT KRT7 PIK3CA PTEN
30 hidradenoma 30.2 AKT1 KRT7 MUC1 PIK3CA
31 thymus cancer 30.2 KIT KRT7 MUC1 TP53
32 thyroid cancer 30.2 AKT1 CCND1 CDH1 HRAS KIT KRAS
33 breast cancer 30.2 AKT1 CCND1 CDH1 ERBB2 FBXW7 HRAS
34 sarcoma, synovial 30.2 CDH1 KIT KRT7 MUC1
35 lung cancer 30.2 AKT1 CCND1 CDH1 ERBB2 HRAS KIT
36 papillary carcinoma 30.2 CDH1 ERBB2 KRT7 MUC1
37 gastric cancer 30.2 AKT1 CCND1 CDH1 ERBB2 KRAS PIK3CA
38 spindle cell carcinoma 30.2 CDH1 KRT14 KRT7 MUC1
39 lung cancer susceptibility 3 30.2 AKT1 CCND1 CDH1 ERBB2 HRAS IDH1
40 carcinosarcoma 30.1 ERBB2 HRAS KIT KRAS KRT7 MUC1
41 brooke-spiegler syndrome 30.1 CYLD KRT14 KRT7
42 cervical adenoid cystic carcinoma 12.7
43 trachea adenoid cystic carcinoma 12.5
44 maxillary sinus adenoid cystic carcinoma 12.5
45 lacrimal gland adenoid cystic carcinoma 12.5
46 esophageal adenoid cystic carcinoma 12.5
47 laryngeal adenoid cystic carcinoma 12.5
48 bartholin's gland adenoid cystic carcinoma 12.5
49 parotid gland adenoid cystic carcinoma 12.5
50 cribriform carcinoma 12.4

Graphical network of the top 20 diseases related to Adenoid Cystic Carcinoma:



Diseases related to Adenoid Cystic Carcinoma

Symptoms & Phenotypes for Adenoid Cystic Carcinoma

UMLS symptoms related to Adenoid Cystic Carcinoma:


pain

GenomeRNAi Phenotypes related to Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

26 (show top 50) (show all 66)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.93 HRAS KRAS PIK3CA MUC1
2 Decreased viability GR00106-A-0 10.93 KRAS
3 Decreased viability GR00221-A-1 10.93 AKT1 CYLD HRAS KRAS PIK3CA CDH1
4 Decreased viability GR00221-A-2 10.93 AKT1 CYLD HRAS KRAS PIK3CA
5 Decreased viability GR00221-A-3 10.93 AKT1 HRAS
6 Decreased viability GR00221-A-4 10.93 AKT1 PIK3CA
7 Decreased viability GR00301-A 10.93 CYLD KRAS CDH1 KIT
8 Decreased viability GR00381-A-1 10.93 KRAS
9 Decreased viability GR00402-S-2 10.93 AKT1 CYLD HRAS KRAS PIK3CA CDH1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.42 MYB
11 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.42 NFIB
12 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.42 KRAS
13 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.42 NFIB
14 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.42 KRAS MYB
15 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.42 FBXW7 MYB
16 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.42 FBXW7 MYB
17 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.42 CCND1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-147 10.42 MYB
19 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.42 CCND1 FBXW7
20 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.42 FBXW7 PIK3CA
21 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.42 AKT1 CCND1 PIK3CA
22 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.42 MYB
23 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.42 CCND1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.42 MYB
25 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.42 PIK3CA
26 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.42 KRAS
27 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.42 MYB
28 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.42 AKT1 CCND1 FBXW7 KRAS MYB NFIB
29 Increased shRNA abundance (Z-score > 2) GR00366-A-183 10.42 FBXW7
30 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.42 PIK3CA
31 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.42 KRAS
32 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.42 CCND1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.42 CCND1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.42 CCND1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.42 KRAS
36 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.42 CCND1 NFIB
37 Increased shRNA abundance (Z-score > 2) GR00366-A-35 10.42 NFIB
38 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.42 CCND1
39 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.42 AKT1 PIK3CA
40 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.42 FBXW7
41 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.42 KRAS PIK3CA
42 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.42 AKT1 KRAS
43 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.42 FBXW7
44 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.42 KRAS
45 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.42 AKT1
46 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.42 MYB
47 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10.42 AKT1
48 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.42 MYB
49 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.42 AKT1
50 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.42 KRAS

MGI Mouse Phenotypes related to Adenoid Cystic Carcinoma:

46 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.51 AKT1 CCND1 CDH1 CYLD ERBB2 FBXW7
2 endocrine/exocrine gland MP:0005379 10.51 AKT1 CCND1 CDH1 CYLD ERBB2 FBXW7
3 growth/size/body region MP:0005378 10.51 AKT1 CCND1 CDH1 CYLD ERBB2 FBXW7
4 homeostasis/metabolism MP:0005376 10.49 AKT1 CCND1 CDH1 CYLD ERBB2 FBXW7
5 mortality/aging MP:0010768 10.46 AKT1 CCND1 CDH1 CYLD ERBB2 FBXW7
6 digestive/alimentary MP:0005381 10.44 CCND1 CDH1 CYLD ERBB2 FBXW7 HRAS
7 cardiovascular system MP:0005385 10.43 AKT1 CCND1 CDH1 ERBB2 FBXW7 HRAS
8 immune system MP:0005387 10.42 AKT1 CCND1 CDH1 CYLD FBXW7 IDH1
9 integument MP:0010771 10.41 AKT1 CCND1 CDH1 CYLD ERBB2 FBXW7
10 hematopoietic system MP:0005397 10.38 AKT1 CCND1 CYLD FBXW7 IDH1 JAK3
11 embryo MP:0005380 10.33 AKT1 CDH1 ERBB2 FBXW7 KIT KRAS
12 neoplasm MP:0002006 10.32 AKT1 CCND1 CDH1 CYLD ERBB2 FBXW7
13 craniofacial MP:0005382 10.3 CCND1 ERBB2 FBXW7 HRAS KIT KRAS
14 nervous system MP:0003631 10.23 AKT1 CCND1 ERBB2 FBXW7 HRAS KIT
15 normal MP:0002873 10.22 AKT1 CCND1 CDH1 CYLD ERBB2 FBXW7
16 liver/biliary system MP:0005370 10.13 AKT1 FBXW7 KIT KRAS MYB NOTCH1
17 muscle MP:0005369 10.1 AKT1 ERBB2 KIT KRAS NOTCH1 PIK3CA
18 respiratory system MP:0005388 10 AKT1 CCND1 CYLD ERBB2 FBXW7 HRAS
19 no phenotypic analysis MP:0003012 9.98 CDH1 HRAS KIT KRAS MYB PIK3CA
20 reproductive system MP:0005389 9.96 AKT1 CCND1 CDH1 ERBB2 KIT KRAS
21 renal/urinary system MP:0005367 9.87 HRAS KIT KRAS KRT7 NOTCH1 PTEN
22 pigmentation MP:0001186 9.85 KIT KRAS KRT14 NOTCH1 PTEN TP53
23 skeleton MP:0005390 9.7 AKT1 CCND1 ERBB2 HRAS IDH1 KIT
24 vision/eye MP:0005391 9.32 CCND1 FBXW7 KIT KRAS KRT14 NFIB

Drugs & Therapeutics for Adenoid Cystic Carcinoma

Drugs for Adenoid Cystic Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 170)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
3
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
4
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
5
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
6
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
7
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
8
Docetaxel Approved, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124
9 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
10 Porfiromycin Investigational Phase 3 801-52-5
11 Cola Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
12 Liver Extracts Phase 3,Phase 2,Phase 1,Early Phase 1
13 Anti-Infective Agents Phase 2, Phase 3,Phase 1
14 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
15 Central Nervous System Depressants Phase 3
16 Adjuvants, Anesthesia Phase 3
17 Anesthetics, Intravenous Phase 3
18 Analgesics, Opioid Phase 3
19 Peripheral Nervous System Agents Phase 3,Not Applicable
20 Anesthetics, General Phase 3
21 Analgesics Phase 3
22 Narcotics Phase 3
23 Anesthetics Phase 3
24 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
25 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
26 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 1,Phase 2
27 Alkylating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
28 Mitomycins Phase 3
29 Neurotransmitter Agents Phase 3,Not Applicable
30 Histamine Antagonists Phase 3
31 Psychotropic Drugs Phase 3
32 Antidepressive Agents Phase 3
33
Histamine Phosphate Phase 3 51-74-1 65513
34 Antidepressive Agents, Tricyclic Phase 3
35 Steroid Synthesis Inhibitors Phase 2, Phase 3
36 Hormone Antagonists Phase 2, Phase 3
37 Antifungal Agents Phase 2, Phase 3,Phase 1
38 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
39 Hormones Phase 2, Phase 3,Phase 1
40 Cytochrome P-450 CYP2C19 Inhibitors Phase 2, Phase 3
41 Cytochrome P-450 CYP2C9 Inhibitors Phase 2, Phase 3
42 Cholinergic Agents Phase 3,Not Applicable
43 Autonomic Agents Phase 3,Not Applicable
44 Muscarinic Agonists Phase 3
45 Contraceptive Agents Phase 3
46
Megestrol Phase 3 3562-63-8 19090 3080587
47 Contraceptives, Oral Phase 3
48 Antineoplastic Agents, Hormonal Phase 3
49 Central Nervous System Stimulants Phase 3,Not Applicable
50 Appetite Stimulants Phase 3

Interventional clinical trials:

(show top 50) (show all 121)
# Name Status NCT ID Phase Drugs
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer Completed NCT00002507 Phase 3 mitomycin C;porfiromycin
3 Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract Completed NCT00765440 Phase 3
4 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
5 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
6 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3 fluconazole
7 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
8 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3 megestrol acetate
9 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
10 Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and Neck Unknown status NCT00180921 Phase 2 Imatinib
11 Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy Unknown status NCT01192087 Phase 1, Phase 2 Cetuximab
12 Phase II Study of Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma Unknown status NCT02393820 Phase 2 pazopanib
13 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
14 Study of RAD001 in Adenoid Cystic Carcinoma Completed NCT01152840 Phase 2 RAD001
15 A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands Completed NCT00886132 Phase 2 Sunitinib
16 Dovitinib in Adenoid Cystic Carcinoma Completed NCT01417143 Phase 2 TKI258 (Dovitinib):
17 Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck Completed NCT00581360 Phase 2 doxorubicin and bortezomib
18 Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Completed NCT01558661 Phase 2 AG-013736 (AXITINIB)
19 Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma Completed NCT01524692 Phase 2 Dovitinib (TKI258)
20 A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands Completed NCT01678105 Phase 2 Dovitinib
21 Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma Completed NCT01175980 Phase 2 Vorinostat
22 Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck Completed NCT00077428 Phase 2 bortezomib;doxorubicin hydrochloride
23 Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers Completed NCT00095563 Phase 2 lapatinib ditosylate
24 Gemcitabine in Treating Patients With Recurrent or Metastatic Adenoid Cystic Cancer of the Head and Neck Completed NCT00017498 Phase 2 gemcitabine hydrochloride
25 Nelfinavir in Recurrent Adenoid Cystic Cancer of the Head and Neck Completed NCT01065844 Phase 2 Nelfinavir
26 Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors Completed NCT00859937 Phase 2 Dasatinib
27 Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma Completed NCT01604772 Phase 2 Akt Inhibitor MK2206
28 Imatinib Mesylate in Treating Patients With Salivary Gland Cancer Completed NCT00045669 Phase 2 imatinib mesylate
29 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
30 Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
31 Chemotherapy in Treating Patients With Solid Tumors Completed NCT00003103 Phase 1, Phase 2 docetaxel
32 High-dose ICE With Amifostine Completed NCT00003657 Phase 2 Amifostine;Carboplatin;Etoposide;Ifosfamide
33 Docetaxel in Treating Patients With Solid Tumors Completed NCT00003565 Phase 2 docetaxel
34 Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer Completed NCT00448552 Phase 2 capecitabine;oxaliplatin
35 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Mouth Cancer Completed NCT00004901 Phase 1, Phase 2 ethynyluracil;fluorouracil;hydroxyurea
36 Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor Completed NCT00021047 Phase 1, Phase 2 capecitabine;carboplatin;epirubicin hydrochloride
37 Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
38 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
39 Cisplatin or Carboplatin Combined With Gemcitabine in Treating Patients With Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor Completed NCT00079079 Phase 2 carboplatin;cisplatin;gemcitabine hydrochloride
40 Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer Completed NCT00004163 Phase 2 Trastuzumab
41 Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery Completed NCT00003744 Phase 2 gemcitabine
42 Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer Completed NCT00509665 Phase 2 doxorubicin hydrochloride;gemcitabine hydrochloride
43 Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer Completed NCT00021333 Phase 2 cisplatin;paclitaxel
44 Trail Evaluating Particle Therapy With or Without Apatinib for H&N Adenoid Cystic Carcinoma Recruiting NCT02942693 Phase 2 Apatinib
45 Chidamide for Advanced Cephalic and Cervical Adenocystic Carcinoma: Evaluation of Efficiency and Safety Recruiting NCT02883374 Phase 2 Chidamide
46 Chidamide Combined With Cisplatin in Head and Neck Adenoid Cystic Carcinoma (HNACC) Recruiting NCT03639168 Phase 2 Chidamide combined with cisplatin
47 A Study Of AL101 In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations Recruiting NCT03691207 Phase 2 AL101
48 Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer Recruiting NCT03146650 Phase 2
49 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
50 Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer Recruiting NCT03172624 Phase 2 Nivolumab;Ipilimumab

Search NIH Clinical Center for Adenoid Cystic Carcinoma

Cochrane evidence based reviews: carcinoma, adenoid cystic

Genetic Tests for Adenoid Cystic Carcinoma

Anatomical Context for Adenoid Cystic Carcinoma

MalaCards organs/tissues related to Adenoid Cystic Carcinoma:

41
Salivary Gland, Breast, Lung, Trachea, Lymph Node, Tongue, Prostate

Publications for Adenoid Cystic Carcinoma

Articles related to Adenoid Cystic Carcinoma:

(show top 50) (show all 1342)
# Title Authors Year
1
Pretreatment quantitative 18F-FDG PET/CT parameters as a predictor of survival in adenoid cystic carcinoma of the salivary glands. ( 30308429 )
2019
2
Cervical lymph node metastases in salivary gland adenoid cystic carcinoma: a systematic review and meta-analysis. ( 29970966 )
2018
3
Effects of para-toluenesulfonamide intratumoral injection on pulmonary adenoid cystic carcinoma complicating with severe central airway obstruction: a 5-year follow-up study. ( 29850151 )
2018
4
Liver resection for metastases of tracheal adenoid cystic carcinoma: Report of two cases. ( 29778031 )
2018
5
Genetic rearrangements, hotspot mutations, and microRNA expression in the progression of metastatic adenoid cystic carcinoma of the salivary gland. ( 29731974 )
2018
6
Central airway obstruction caused by adenoid cystic carcinoma in pregnancy: a case report and review of the literature. ( 29721318 )
2018
7
Inhibitory effect of chidamide on the growth of human adenoid cystic carcinoma cells. ( 29710459 )
2018
8
Deregulation of Nicotinamide N-Methyltransferase and Gap Junction Protein Alpha-1 Causes Metastasis in Adenoid Cystic Carcinoma. ( 29277772 )
2018
9
EGFR activation induced Snail-dependent EMT and myc-dependent PD-L1 in human salivary adenoid cystic carcinoma cells. ( 29954240 )
2018
10
Ataxia-Telangiectasia-Mutated Protein Expression as a Prognostic Marker in Adenoid Cystic Carcinoma of the Salivary Glands. ( 29978608 )
2018
11
Discordant correlation of breast adenoid cystic carcinoma on imaging and pathology: A case report and literature review on surgical management. ( 29268125 )
2018
12
Potential biological functions of microvesicles derived from adenoid cystic carcinoma. ( 29725477 )
2018
13
Expression of PIM-1 in salivary gland adenoid cystic carcinoma: Association with tumor progression and patients' prognosis. ( 29399171 )
2018
14
3D-printing aided resection of intratracheal adenoid cystic carcinoma and mediastinal mature cystic teratoma in a 26-year-old female: a case report. ( 29607203 )
2018
15
miR-93-5p enhance lacrimal gland adenoid cystic carcinoma cell tumorigenesis by targeting BRMS1L. ( 29760585 )
2018
16
Dedifferentiated adenoid cystic carcinoma ex pleomorphic adenoma of the parotid. ( 29893347 )
2018
17
Alterations of Notch pathway in patients with adenoid cystic carcinoma of the trachea and its impact on survival. ( 29858025 )
2018
18
IGFBP2 promotes salivary adenoid cystic carcinoma metastasis by activating the NF-I_B/ZEB1 signaling pathway. ( 29885520 )
2018
19
Immunohistochemical Expression of CD-117 (c-KIT), P-53 and Ki-67 in Adenoid Cystic Carcinoma of Palate. ( 29866247 )
2018
20
Effect of survivin downregulation by simvastatin on the growth and invasion of salivary adenoid cystic carcinoma. ( 29956779 )
2018
21
Primary Cutaneous Adenoid Cystic Carcinoma Connecting to the Epidermis. ( 29742556 )
2018
22
Sinonasal adenoid cystic carcinoma-role of on-site FNAC: a case report. ( 29760580 )
2018
23
Establishment and characterization of a carcinoma-associated fibroblast cell line derived from a human salivary gland adenoid cystic carcinoma. ( 29734861 )
2018
24
Molecular features of adenoid cystic carcinoma with an emphasis on microRNA expression. ( 29924420 )
2018
25
Hydrogen Sulfide and Hydrogen Sulfide-Synthesizing Enzymes Are Altered in a Case of Oral Adenoid Cystic Carcinoma. ( 30283315 )
2018
26
Adenoid cystic carcinoma: A study of 19 cases of salivary and extra-salivary tumours diagnosed by fine needle aspiration cytology. ( 30284389 )
2018
27
Role of Noxa in proliferation, apoptosis, and autophagy in human adenoid cystic carcinoma. ( 30290043 )
2018
28
Abnormal activation of the Akt signaling pathway in adenoid cystic carcinoma. ( 30367261 )
2018
29
Emergency Tracheal Surgery for Adenoid Cystic Carcinoma: A Rare Entity. ( 30369385 )
2018
30
Spinal Metastases from Adenoid Cystic Carcinoma of the Parotid Gland. ( 30381599 )
2018
31
Advanced adenoid cystic carcinoma (ACC) is featured by SWI/SNF chromatin remodeling complex aberrations. ( 30382367 )
2018
32
Expression of EpCAM in adenoid cystic carcinoma. ( 30389218 )
2018
33
Overexpression Cathepsin D Contributes to Perineural Invasion of Salivary Adenoid Cystic Carcinoma. ( 30430081 )
2018
34
Molecular methods for detection of prognostic and predictive markers in diagnosis of adenoid cystic carcinoma of the salivary gland origin. ( 30445817 )
2018
35
Prognostic factors and survival in adenoid cystic carcinoma of the sinonasal cavity. ( 30447126 )
2018
36
Endoscopic endonasal resection of adenoid cystic carcinoma of the sinonasal tract and skull base. ( 30450555 )
2018
37
Dosimetric advantages of stereotactic radiosurgery as a boost to adjuvant conventional radiotherapy in the setting of adenoid cystic carcinoma of the parotid with skull base invasion. ( 30455905 )
2018
38
Metastasis of adenoid cystic carcinoma from a submandibular gland to the larynx. ( 30473272 )
2018
39
Adenoid Cystic Carcinoma With Sialolithiasis of the Left Submandibular Gland: A Case Report and Literature Review. ( 30482073 )
2018
40
A case of sublingual adenoid cystic carcinoma involving the mandible presenting as a "skip lesion". ( 30484035 )
2018
41
Oropharyngeal adenoid cystic carcinoma invading the mandibular bone through the mandibular foramen. ( 30484215 )
2018
42
Predictors of nodal metastasis and prognostic significance of lymph node ratio and total lymph node count in tracheobronchial adenoid cystic carcinoma. ( 30510459 )
2018
43
Intensity Modulated Radiotherapy (IMRT) + Carbon Ion Boost for Adenoid Cystic Carcinoma of the Minor Salivary Glands in the Oral Cavity. ( 30518108 )
2018
44
UM-HACC-2A: MYB-NFIB fusion-positive human adenoid cystic carcinoma cell line. ( 30527239 )
2018
45
Complete remission after hypofractionated radiotherapy for a patient with inoperable adenoid cystic carcinoma of bronchus: A case report. ( 30544432 )
2018
46
18 F-FDG PET/MRI vs MRI in patients with recurrent adenoid cystic carcinoma. ( 30548894 )
2018
47
Tumor-derived exosomes enhance invasion and metastasis of salivary adenoid cystic carcinoma cells. ( 29057556 )
2018
48
Cellular subtype may predict survival outcomes in salivary adenoid cystic carcinoma patients-a single-institution experience. ( 29063189 )
2018
49
The Prognostic Significance of Notch1 and Fatty Acid Binding Protein 7 (FABP7) Expression in Resected Tracheobronchial Adenoid Cystic Carcinoma: A Multicenter Retrospective Study. ( 29141398 )
2018
50
A Favorable Response to Levetiracetam in a Patient with Metastatic Adenoid Cystic Carcinoma. ( 29151513 )
2018

Variations for Adenoid Cystic Carcinoma

ClinVar genetic disease variations for Adenoid Cystic Carcinoma:

6 (show top 50) (show all 118)
# Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
2 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
3 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
4 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
5 KRAS NM_033360.3(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
6 KRAS NM_033360.3(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 GRCh38 Chromosome 12, 25245351: 25245351
7 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
8 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
9 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
10 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
11 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
12 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
13 PIK3CA NM_006218.3(PIK3CA): c.1258T> C (p.Cys420Arg) single nucleotide variant Pathogenic rs121913272 GRCh37 Chromosome 3, 178927980: 178927980
14 PIK3CA NM_006218.3(PIK3CA): c.1258T> C (p.Cys420Arg) single nucleotide variant Pathogenic rs121913272 GRCh38 Chromosome 3, 179210192: 179210192
15 CREBBP NM_004380.2(CREBBP): c.4336C> T (p.Arg1446Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs398124146 GRCh37 Chromosome 16, 3788618: 3788618
16 CREBBP NM_004380.2(CREBBP): c.4336C> T (p.Arg1446Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs398124146 GRCh38 Chromosome 16, 3738617: 3738617
17 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211
18 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic rs587778720 GRCh38 Chromosome 17, 7674893: 7674893
19 IDH1 NM_001282386.1(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh38 Chromosome 2, 208248388: 208248388
20 IDH1 NM_001282386.1(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh37 Chromosome 2, 209113112: 209113112
21 PIK3CA NM_006218.3(PIK3CA): c.3129G> A (p.Met1043Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913283 GRCh38 Chromosome 3, 179234286: 179234286
22 PIK3CA NM_006218.3(PIK3CA): c.3129G> A (p.Met1043Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913283 GRCh37 Chromosome 3, 178952074: 178952074
23 TP53 NM_000546.5(TP53): c.638G> C (p.Arg213Pro) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211
24 TP53 NM_000546.5(TP53): c.638G> C (p.Arg213Pro) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh38 Chromosome 17, 7674893: 7674893
25 JAK3 NM_000215.3(JAK3): c.1765G> A (p.Gly589Ser) single nucleotide variant Pathogenic rs886039394 GRCh37 Chromosome 19, 17947959: 17947959
26 JAK3 NM_000215.3(JAK3): c.1765G> A (p.Gly589Ser) single nucleotide variant Pathogenic rs886039394 GRCh38 Chromosome 19, 17837150: 17837150
27 IDH1 NM_005896.3(IDH1): c.395G> T (p.Arg132Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh37 Chromosome 2, 209113112: 209113112
28 IDH1 NM_005896.3(IDH1): c.395G> T (p.Arg132Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh38 Chromosome 2, 208248388: 208248388
29 IDH1 NM_001282387.1(IDH1): c.394C> T (p.Arg132Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh37 Chromosome 2, 209113113: 209113113
30 IDH1 NM_001282387.1(IDH1): c.394C> T (p.Arg132Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh38 Chromosome 2, 208248389: 208248389
31 IDH1 NM_001282387.1(IDH1): c.394C> G (p.Arg132Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh37 Chromosome 2, 209113113: 209113113
32 IDH1 NM_001282387.1(IDH1): c.394C> G (p.Arg132Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh38 Chromosome 2, 208248389: 208248389
33 IDH1 NM_001282387.1(IDH1): c.394C> A (p.Arg132Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh37 Chromosome 2, 209113113: 209113113
34 IDH1 NM_001282387.1(IDH1): c.394C> A (p.Arg132Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh38 Chromosome 2, 208248389: 208248389
35 PIK3CA NM_006218.3(PIK3CA): c.1035T> A (p.Asn345Lys) single nucleotide variant Likely pathogenic rs121913284 GRCh37 Chromosome 3, 178921553: 178921553
36 PIK3CA NM_006218.3(PIK3CA): c.1035T> A (p.Asn345Lys) single nucleotide variant Likely pathogenic rs121913284 GRCh38 Chromosome 3, 179203765: 179203765
37 CREBBP NM_004380.2(CREBBP): c.4337G> T (p.Arg1446Leu) single nucleotide variant Likely pathogenic rs1057519884 GRCh37 Chromosome 16, 3788617: 3788617
38 CREBBP NM_004380.2(CREBBP): c.4337G> T (p.Arg1446Leu) single nucleotide variant Likely pathogenic rs1057519884 GRCh38 Chromosome 16, 3738616: 3738616
39 CREBBP NM_004380.2(CREBBP): c.4337G> A (p.Arg1446His) single nucleotide variant Likely pathogenic rs1057519884 GRCh37 Chromosome 16, 3788617: 3788617
40 CREBBP NM_004380.2(CREBBP): c.4337G> A (p.Arg1446His) single nucleotide variant Likely pathogenic rs1057519884 GRCh38 Chromosome 16, 3738616: 3738616
41 CREBBP NM_004380.2(CREBBP): c.4336C> G (p.Arg1446Gly) single nucleotide variant Likely pathogenic rs398124146 GRCh37 Chromosome 16, 3788618: 3788618
42 CREBBP NM_004380.2(CREBBP): c.4336C> G (p.Arg1446Gly) single nucleotide variant Likely pathogenic rs398124146 GRCh38 Chromosome 16, 3738617: 3738617
43 FBXW7 NM_018315.4(FBXW7): c.1153C> T (p.Arg385Cys) single nucleotide variant Likely pathogenic rs867384286 GRCh37 Chromosome 4, 153249385: 153249385
44 FBXW7 NM_018315.4(FBXW7): c.1153C> T (p.Arg385Cys) single nucleotide variant Likely pathogenic rs867384286 GRCh38 Chromosome 4, 152328233: 152328233
45 FBXW7 NM_018315.4(FBXW7): c.1154G> A (p.Arg385His) single nucleotide variant Likely pathogenic rs1057519895 GRCh37 Chromosome 4, 153249384: 153249384
46 FBXW7 NM_018315.4(FBXW7): c.1154G> A (p.Arg385His) single nucleotide variant Likely pathogenic rs1057519895 GRCh38 Chromosome 4, 152328232: 152328232
47 FBXW7 NM_018315.4(FBXW7): c.1154G> C (p.Arg385Pro) single nucleotide variant Likely pathogenic rs1057519895 GRCh37 Chromosome 4, 153249384: 153249384
48 FBXW7 NM_018315.4(FBXW7): c.1154G> C (p.Arg385Pro) single nucleotide variant Likely pathogenic rs1057519895 GRCh38 Chromosome 4, 152328232: 152328232
49 FBXW7 NM_001013415.1(FBXW7): c.1040G> T (p.Arg347Leu) single nucleotide variant Likely pathogenic rs1057519895 GRCh37 Chromosome 4, 153249384: 153249384
50 FBXW7 NM_001013415.1(FBXW7): c.1040G> T (p.Arg347Leu) single nucleotide variant Likely pathogenic rs1057519895 GRCh38 Chromosome 4, 152328232: 152328232

Cosmic variations for Adenoid Cystic Carcinoma:

9 (show top 50) (show all 14022)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6939530 TSC2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2402C>T p.A801V 16:2074246-2074246 30
2 COSM6939527 TSC1 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2684T>A p.V895D 9:132897552-132897552 30
3 COSM43878 TP53 salivary gland,major,carcinoma,adenoid cystic carcinoma c.427G>A p.V143M 17:7675185-7675185 30
4 COSM6935085 TENT5C salivary gland,minor,carcinoma,adenoid cystic carcinoma c.833T>A p.F278Y 1:117623701-117623701 30
5 COSM6939534 STAG2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2405T>G p.I802S 23:124071195-124071195 30
6 COSM6939532 SOX9 salivary gland,major,carcinoma,adenoid cystic carcinoma c.1457T>A p.V486D 17:72124314-72124314 30
7 COSM6939526 SMO salivary gland,major,carcinoma,adenoid cystic carcinoma c.385G>C p.V129L 7:129203437-129203437 30
8 COSM6915408 SF3B1 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.3254C>T p.A1085V 2:197397997-197397997 30
9 COSM6910358 SETD2 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.4870C>T p.Q1624* 3:47057405-47057405 30
10 COSM41699 RUNX1 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.958C>T p.R320* 21:34799310-34799310 30
11 COSM6928612 RPTOR salivary gland,minor,carcinoma,adenoid cystic carcinoma c.734C>T p.A245V 17:80754089-80754089 30
12 COSM1644939 RB1 salivary gland,major,carcinoma,adenoid cystic carcinoma c.1817A>G p.Y606C 13:48456206-48456206 30
13 COSM6913929 RASA1 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2603+2T>A p.? 5:87379852-87379852 30
14 COSM6910894 RASA1 salivary gland,major,carcinoma,adenoid cystic carcinoma c.3026T>G p.L1009R 5:87389493-87389493 30
15 COSM6910364 RARA salivary gland,minor,carcinoma,adenoid cystic carcinoma c.691C>G p.L231V 17:40352391-40352391 30
16 COSM3219585 PTPRD salivary gland,major,carcinoma,adenoid cystic carcinoma c.3542G>A p.R1181H 9:8465638-8465638 30
17 COSM1110409 PTPRD salivary gland,major,carcinoma,adenoid cystic carcinoma c.5473G>C p.G1825R 9:8331643-8331643 30
18 COSM5046 PTEN salivary gland,major,carcinoma,adenoid cystic carcinoma c.764T>C p.V255A 10:87957982-87957982 30
19 COSM51211 PPP2R1A salivary gland,major,carcinoma,adenoid cystic carcinoma c.547C>T p.R183W 19:52212729-52212729 30
20 COSM6935088 PIK3CG salivary gland,minor,carcinoma,adenoid cystic carcinoma c.2951C>A p.P984Q 7:106886213-106886213 30
21 COSM775 PIK3CA salivary gland,major,carcinoma,adenoid cystic carcinoma c.3140A>G p.H1047R 3:179234297-179234297 30
22 COSM757 PIK3CA salivary gland,minor,carcinoma,adenoid cystic carcinoma c.1258T>C p.C420R 3:179210192-179210192 30
23 COSM6960739 PIK3C2G salivary gland,major,carcinoma,adenoid cystic carcinoma c.1852C>G p.P618A 12:18381860-18381860 30
24 COSM6939528 PGR salivary gland,major,carcinoma,adenoid cystic carcinoma c.1604C>G p.P535R 11:101127467-101127467 30
25 COSM6959277 NTRK2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2158A>T p.T720S 9:84955503-84955503 30
26 COSM6916607 NTRK2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2336T>C p.I779T 9:85021256-85021256 30
27 COSM6909937 NOTCH1 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.973A>G p.N325D 9:136518717-136518717 30
28 COSM6916910 NOTCH1 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.403+1G>C p.? 9:136523716-136523716 30
29 COSM13044 NOTCH1 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.5101G>C p.A1701P 9:136503248-136503248 30
30 COSM3929943 NOTCH1 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.1367G>A p.C456Y 9:136517826-136517826 30
31 COSM13081 NOTCH1 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.7400C>A p.S2467* 9:136496339-136496339 30
32 COSM6910892 MYCN salivary gland,major,carcinoma,adenoid cystic carcinoma c.1336A>G p.K446E 2:15946038-15946038 30
33 COSM6911643 MET salivary gland,major,carcinoma,adenoid cystic carcinoma c.1249C>G p.R417G 7:116731716-116731716 30
34 COSM6910361 MAX salivary gland,minor,carcinoma,adenoid cystic carcinoma c.295+1G>A p.? 14:65077912-65077912 30
35 COSM4042348 KMT2D salivary gland,minor,carcinoma,adenoid cystic carcinoma c.12640C>T p.R4214* 12:49031255-49031255 30
36 COSM6927891 KMT2D salivary gland,major,carcinoma,adenoid cystic carcinoma c.3587G>A p.W1196* 12:49046621-49046621 30
37 COSM6909196 KMT2D salivary gland,major,carcinoma,adenoid cystic carcinoma c.9308C>A p.S3103* 12:49037238-49037238 30
38 COSM51381 KIT salivary gland,face,carcinoma,adenoid cystic carcinoma c.2386A>G p.R796G 4:54733094-54733094 30
39 COSM5609233 KDR salivary gland,major,carcinoma,adenoid cystic carcinoma c.2524C>T p.R842C 4:55097752-55097752 30
40 COSM6911645 KDM6A salivary gland,major,carcinoma,adenoid cystic carcinoma c.3625A>G p.R1209G 23:45089819-45089819 30
41 COSM5696749 KDM6A salivary gland,major,carcinoma,adenoid cystic carcinoma c.3736+2T>C p.? 23:45089932-45089932 30
42 COSM6955991 KDM5A salivary gland,major,carcinoma,adenoid cystic carcinoma c.1186C>T p.R396W 12:350743-350743 30
43 COSM6913928 JAK1 salivary gland,major,carcinoma,adenoid cystic carcinoma c.3310C>T p.L1104F 1:64835455-64835455 30
44 COSM6925975 HGF salivary gland,minor,carcinoma,adenoid cystic carcinoma c.1444+1G>A p.? 7:81711480-81711480 30
45 COSM6910893 FOXP1 salivary gland,major,carcinoma,adenoid cystic carcinoma c.1930G>T p.E644* 3:70959351-70959351 30
46 COSM6910360 FGFR3 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.1682G>C p.G561A 4:1805786-1805786 30
47 COSM6916439 EZH2 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.938G>A p.R313Q 7:148819657-148819657 30
48 COSM6935087 ETV1 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.971G>T p.R324L 7:13906569-13906569 30
49 COSM6938635 ERBB3 salivary gland,major,carcinoma,adenoid cystic carcinoma c.917C>G p.P306R 12:56088585-56088585 30
50 COSM6955992 ERBB2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2126A>T p.Q709L 17:39723578-39723578 30

Copy number variations for Adenoid Cystic Carcinoma from CNVD:

7 (show top 50) (show all 209)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13805 1 1 61300000 Deletion Adenoid cystic carcinoma
2 31809 1 31200000 32688000 Loss BAI2 Adenoid cystic carcinoma
3 31810 1 31200000 32688000 Loss EIF3S2 Adenoid cystic carcinoma
4 31811 1 31200000 32688000 Loss FABP3 Adenoid cystic carcinoma
5 31812 1 31200000 32688000 Loss HDAC1 Adenoid cystic carcinoma
6 31813 1 31200000 32688000 Loss IQCC Adenoid cystic carcinoma
7 31814 1 31200000 32688000 Loss KHDRBS1 Adenoid cystic carcinoma
8 31815 1 31200000 32688000 Loss LCK Adenoid cystic carcinoma
9 31816 1 31200000 32688000 Loss MARCKSL1 Adenoid cystic carcinoma
10 31817 1 31200000 32688000 Loss PTP4A2 Adenoid cystic carcinoma
11 31818 1 31200000 32688000 Loss PUM1 Adenoid cystic carcinoma
12 31819 1 31200000 32688000 Loss RBBP4 Adenoid cystic carcinoma
13 31820 1 31200000 32688000 Loss SERINC2 Adenoid cystic carcinoma
14 31821 1 31200000 32688000 Loss TXLNA Adenoid cystic carcinoma
15 33928 1 50618000 52179000 Loss CDKN2C Adenoid cystic carcinoma
16 33929 1 50618000 52179000 Loss EPS15 Adenoid cystic carcinoma
17 33930 1 50618000 52179000 Loss FAF1 Adenoid cystic carcinoma
18 33931 1 50618000 52179000 Loss NRD1 Adenoid cystic carcinoma
19 33932 1 50618000 52179000 Loss RAB3B Adenoid cystic carcinoma
20 33933 1 50618000 52179000 Loss RNF11 Adenoid cystic carcinoma
21 50143 11 114500000 121200000 Deletion Adenoid cystic carcinoma
22 50146 11 114500000 121200000 Gain Salivary gland adenoid cystic carcinoma
23 58545 11 68400000 70400000 Deletion Adenoid cystic carcinoma
24 58546 11 68400000 70400000 Gain Salivary gland adenoid cystic carcinoma
25 61970 12 103800000 109000000 LOH Adenoid cystic carcinoma
26 64283 12 125900000 133851895 LOH Adenoid cystic carcinoma
27 67068 12 35800000 133851895 Loss Adenoid cystic carcinoma
28 67236 12 38200000 58100000 Deletion Adenoid cystic carcinoma
29 67639 12 43743000 50676000 Loss ACVR1B Adenoid cystic carcinoma
30 67640 12 43743000 50676000 Loss ACVRL1 Adenoid cystic carcinoma
31 67641 12 43743000 50676000 Loss ADCY6 Adenoid cystic carcinoma
32 67642 12 43743000 50676000 Loss AMIGO2 Adenoid cystic carcinoma
33 67643 12 43743000 50676000 Loss ANP32D Adenoid cystic carcinoma
34 67644 12 43743000 50676000 Loss ARF3 Adenoid cystic carcinoma
35 67645 12 43743000 50676000 Loss ATF1 Adenoid cystic carcinoma
36 67646 12 43743000 50676000 Loss CCNT1 Adenoid cystic carcinoma
37 67647 12 43743000 50676000 Loss COL2A1 Adenoid cystic carcinoma
38 67648 12 43743000 50676000 Loss DDX23 Adenoid cystic carcinoma
39 67649 12 43743000 50676000 Loss FAIM2 Adenoid cystic carcinoma
40 67650 12 43743000 50676000 Loss HDAC7A Adenoid cystic carcinoma
41 67651 12 43743000 50676000 Loss LALBA Adenoid cystic carcinoma
42 67652 12 43743000 50676000 Loss LETMD1 Adenoid cystic carcinoma
43 67653 12 43743000 50676000 Loss LIMA1 Adenoid cystic carcinoma
44 67654 12 43743000 50676000 Loss MLL2 Adenoid cystic carcinoma
45 67655 12 43743000 50676000 Loss PFKM Adenoid cystic carcinoma
46 67656 12 43743000 50676000 Loss PLEKHA9 Adenoid cystic carcinoma
47 67657 12 43743000 50676000 Loss PRKAG1 Adenoid cystic carcinoma
48 67658 12 43743000 50676000 Loss RACGAP1 Adenoid cystic carcinoma
49 67659 12 43743000 50676000 Loss RAPGEF3 Adenoid cystic carcinoma
50 67660 12 43743000 50676000 Loss RHEBL1 Adenoid cystic carcinoma

Expression for Adenoid Cystic Carcinoma

Search GEO for disease gene expression data for Adenoid Cystic Carcinoma.

Pathways for Adenoid Cystic Carcinoma

Pathways related to Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 139)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.31 AKT1 CCND1 CDH1 CYLD ERBB2 FBXW7
2
Show member pathways
14.13 AKT1 CCND1 CDH1 CYLD ERBB2 FBXW7
3
Show member pathways
13.99 AKT1 CCND1 CDH1 ERBB2 HRAS JAK3
4
Show member pathways
13.85 AKT1 CDH1 ERBB2 FBXW7 HRAS IDH1
5
Show member pathways
13.83 AKT1 CCND1 ERBB2 HRAS JAK3 KIT
6
Show member pathways
13.67 AKT1 CDH1 ERBB2 HRAS JAK3 KIT
7
Show member pathways
13.63 AKT1 ERBB2 HRAS JAK3 KIT KRAS
8
Show member pathways
13.58 AKT1 CDH1 ERBB2 FBXW7 HRAS KIT
9
Show member pathways
13.55 AKT1 CCND1 ERBB2 HRAS JAK3 KIT
10
Show member pathways
13.48 AKT1 CCND1 ERBB2 HRAS JAK3 KIT
11
Show member pathways
13.44 AKT1 CDH1 ERBB2 HRAS KIT KRAS
12
Show member pathways
13.42 AKT1 HRAS JAK3 KRAS MYB PIK3CA
13
Show member pathways
13.35 AKT1 CCND1 ERBB2 HRAS JAK3 KRAS
14
Show member pathways
13.21 AKT1 ERBB2 KIT PIK3CA PTEN TP53
15
Show member pathways
13.2 AKT1 CCND1 HRAS KRAS PIK3CA PTEN
16
Show member pathways
13.17 AKT1 HRAS KIT KRAS PTEN TP53
17
Show member pathways
13.06 AKT1 HRAS KRAS PIK3CA PTEN TP53
18
Show member pathways
13.05 AKT1 CCND1 ERBB2 HRAS KRAS PIK3CA
19
Show member pathways
13.03 AKT1 HRAS KIT KRAS PIK3CA TP53
20
Show member pathways
13.03 AKT1 ERBB2 HRAS KRAS PIK3CA PTEN
21
Show member pathways
13.01 AKT1 CCND1 HRAS JAK3 KRAS PIK3CA
22
Show member pathways
13.01 AKT1 ERBB2 HRAS JAK3 KRAS PIK3CA
23
Show member pathways
12.99 AKT1 CCND1 ERBB2 HRAS JAK3 KIT
24
Show member pathways
12.94 AKT1 CCND1 CDH1 ERBB2 HRAS KIT
25
Show member pathways
12.92 AKT1 CCND1 HRAS JAK3 KRAS PIK3CA
26 12.91 AKT1 ERBB2 HRAS KIT KRAS TP53
27
Show member pathways
12.9 AKT1 HRAS KRAS PIK3CA TP53
28
Show member pathways
12.89 AKT1 CCND1 JAK3 PIK3CA TP53
29
Show member pathways
12.88 AKT1 CDH1 HRAS KIT KRAS PIK3CA
30
Show member pathways
12.86 AKT1 ERBB2 HRAS KIT KRAS PIK3CA
31
Show member pathways
12.84 AKT1 CDH1 ERBB2 HRAS KRAS PIK3CA
32
Show member pathways
12.82 AKT1 CCND1 HRAS KRAS PIK3CA PTEN
33
Show member pathways
12.79 AKT1 HRAS JAK3 KRAS TP53
34
Show member pathways
12.74 AKT1 ERBB2 HRAS KRAS PIK3CA TP53
35
Show member pathways
12.73 AKT1 CCND1 CDH1 ERBB2 HRAS JAK3
36
Show member pathways
12.71 AKT1 HRAS KRAS PIK3CA PTEN
37
Show member pathways
12.66 AKT1 ERBB2 HRAS KRAS PIK3CA PTEN
38
Show member pathways
12.66 AKT1 CCND1 CDH1 ERBB2 HRAS KIT
39 12.65 AKT1 CCND1 CDH1 ERBB2 HRAS JAK3
40
Show member pathways
12.64 AKT1 CCND1 ERBB2 HRAS KRAS PIK3CA
41 12.64 CCND1 ERBB2 HRAS KRAS NOTCH1 PIK3CA
42
Show member pathways
12.63 AKT1 CCND1 ERBB2 HRAS KRAS PIK3CA
43
Show member pathways
12.6 AKT1 CCND1 CDH1 ERBB2 HRAS KRAS
44
Show member pathways
12.59 AKT1 ERBB2 HRAS KRAS PIK3CA TP53
45
Show member pathways
12.58 AKT1 CCND1 HRAS PIK3CA TP53
46
Show member pathways
12.56 AKT1 CCND1 HRAS JAK3 KRAS PIK3CA
47
Show member pathways
12.55 AKT1 HRAS KIT KRAS PIK3CA
48
Show member pathways
12.55 AKT1 HRAS JAK3 KRAS PIK3CA
49
Show member pathways
12.54 CDH1 ERBB2 HRAS KIT KRAS PIK3CA
50
Show member pathways
12.53 AKT1 HRAS KRAS PIK3CA PTEN

GO Terms for Adenoid Cystic Carcinoma

Cellular components related to Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.83 AKT1 CCND1 CYLD ERBB2 FBXW7 HRAS
2 cytoplasm GO:0005737 9.58 AKT1 CCND1 CDH1 CYLD ERBB2 FBXW7
3 cytoplasmic side of plasma membrane GO:0009898 9.33 CDH1 KIT PTEN

Biological processes related to Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.98 HRAS NFIB NOTCH1 PTEN TP53
2 cell proliferation GO:0008283 9.95 AKT1 ERBB2 HRAS PTEN TP53
3 negative regulation of gene expression GO:0010629 9.93 AKT1 FBXW7 HRAS NOTCH1
4 MAPK cascade GO:0000165 9.83 ERBB2 HRAS JAK3 KIT KRAS
5 positive regulation of cell proliferation GO:0008284 9.8 AKT1 CCND1 HRAS KIT KRAS NOTCH1
6 Ras protein signal transduction GO:0007265 9.78 HRAS KRAS TP53
7 positive regulation of protein phosphorylation GO:0001934 9.77 AKT1 CCND1 ERBB2 HRAS KRAS
8 response to organic substance GO:0010033 9.76 AKT1 CCND1 CDH1 PTEN
9 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.75 HRAS KRAS MUC1
10 positive regulation of epithelial cell proliferation GO:0050679 9.74 ERBB2 HRAS NOTCH1
11 liver development GO:0001889 9.71 CCND1 KRAS NOTCH1 PIK3CA
12 protein kinase B signaling GO:0043491 9.69 AKT1 PIK3CA PTEN
13 phosphatidylinositol 3-kinase signaling GO:0014065 9.65 AKT1 ERBB2 PIK3CA
14 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.63 ERBB2 FBXW7 HRAS KIT NOTCH1 PTEN
15 anoikis GO:0043276 9.62 AKT1 PIK3CA
16 negative regulation of cell size GO:0045792 9.62 AKT1 PTEN
17 positive regulation of MAP kinase activity GO:0043406 9.62 ERBB2 HRAS KIT KRAS
18 somatic stem cell division GO:0048103 9.61 KIT NOTCH1
19 enzyme linked receptor protein signaling pathway GO:0007167 9.6 ERBB2 JAK3
20 mitotic G1 DNA damage checkpoint GO:0031571 9.59 CCND1 TP53
21 response to isolation stress GO:0035900 9.56 HRAS KRAS
22 positive regulation of gene expression GO:0010628 9.56 AKT1 ERBB2 HRAS KIT KRAS NOTCH1
23 cellular response to decreased oxygen levels GO:0036294 9.52 AKT1 PTEN
24 response to UV-A GO:0070141 9.49 AKT1 CCND1
25 cytokine-mediated signaling pathway GO:0019221 9.23 AKT1 CCND1 JAK3 KIT KRAS MUC1
26 protein phosphorylation GO:0006468 10.01 AKT1 CCND1 ERBB2 JAK3 KIT PIK3CA

Molecular functions related to Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.91 AKT1 CCND1 CDH1 CYLD ERBB2 FBXW7
2 identical protein binding GO:0042802 9.87 AKT1 CDH1 ERBB2 FBXW7 IDH1 PTEN
3 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.83 MUC1 MYB NFIB NOTCH1 TP53
4 protein kinase binding GO:0019901 9.8 AKT1 CCND1 CYLD PTEN TP53
5 kinase activity GO:0016301 9.73 AKT1 CCND1 ERBB2 JAK3 KIT PIK3CA
6 protein phosphatase binding GO:0019903 9.63 ERBB2 JAK3 TP53
7 enzyme binding GO:0019899 9.55 AKT1 CCND1 NOTCH1 PTEN TP53
8 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.54 ERBB2 KIT PIK3CA
9 nucleotide binding GO:0000166 9.1 AKT1 ERBB2 HRAS JAK3 KIT KRAS

Sources for Adenoid Cystic Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....